VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate COVID-19 in High Risk Patients Reaches Primary Endpoint
–the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint –VV116 has a favorable safety profile and fewer adverse events than PAXLOVID